Cargando…
Targeting HER3 for cancer treatment: a new horizon for an old target
Human epidermal growth factor receptor 3 (HER3) is a member of the human epidermal growth factor receptors family, having as its main ligands neuregulins 1 and 2. Although its poor tyrosine kinase activity entails a weak oncogenic power on its own, HER3 can heterodimerize with HER2 and/or epidermal...
Autores principales: | Uliano, J., Corvaja, C., Curigliano, G., Tarantino, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929675/ https://www.ncbi.nlm.nih.gov/pubmed/36764093 http://dx.doi.org/10.1016/j.esmoop.2023.100790 |
Ejemplares similares
-
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021) -
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023) -
In Vivo Targeting of CXCR4—New Horizons
por: Schottelius, Margret, et al.
Publicado: (2021) -
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
por: Spitaleri, Gianluca, et al.
Publicado: (2023) -
The HER2-low revolution in breast oncology: steps forward and
emerging challenges
por: Nicolò, Eleonora, et al.
Publicado: (2023)